研究疾病:
|
不适用
|
研究疾病代码:
|
|
Target disease:
|
N/A
|
Target disease code:
|
研究类型:
Study type:
|
基础科学研究
Basic Science
|
研究设计:
Study design:
|
随机平行对照
randomized controlled trial(parallel group design)
|
研究所处阶段:
Study phase:
|
探索性研究/预试验
Pilot clinical trial
|
研究目的:
|
本研究利用16sRNA和代谢组学技术,观察银黄含化片对健康人上呼吸道微生态的影响及其在体内的影响机制,旨在探讨银黄含化片能否通过抑制健康人上呼吸道潜在致病菌、调节优势菌群,起到维护口咽部微生态平衡的作用。
|
Objectives of Study:
|
This study used 16sRNA and metabolomics technology to observe the effect of yinghuang tablets on the microecology of the upper respiratory tract of healthy people and its mechanism in vivo, aiming to explore whether yinghuang tablets can play a role in maintaining the microecological balance of oropharynx by inhibiting the potential pathogenic bacteria of the upper respiratory tract of healthy people and regulating the dominant flora.
|
药物成份或治疗方案详述:
|
干预方案
用药期
试验组(30人):银黄含片组:含服银黄含化片7天,一日6次,一次2片。期间禁用任何药物,忌辛辣、烟酒等刺激物。
对照组(30人):含服银黄含化片安慰剂7天,一日6次,一次2片。期间禁用任何药物,忌辛辣、烟酒等刺激物。
试验方法:
(1)嘱研究对象按要求/含服药物,或安慰剂治疗7天,于试验前1天、第8天采集咽拭子和粪便标本。于试验结束后第7天采集咽拭子。
(2)对咽拭子进行宏基因研究,对比对照组、试验组组上呼吸道微生态的各菌群丰度变化。对各组的粪便进行代谢组学研究,寻找与银黄含化片作用相关的潜在生物标志物,分析这些生物标志物在体内的代谢通路。
随访期
于试验结束后第7天再次采集试验组咽拭子1次。
|
Description for medicine or protocol of treatment in detail:
|
Intervention planDrug use periodTest group (30 people) : yinhuang buccal tablets group: yinhuang hanhua tablets for 7 days, 6 times a day, 2 tablets a time.During the prohibition of any drugs, avoid spicy, tobacco and alcohol and other irritants.Control group (30 people) : take yinhuanghanhua tablet placebo for 7 days, 6 times a day, 2 tablets a time.During the prohibition of any drugs, avoid spicy, tobacco and alcohol and other irritants.Test method:(1) subjects were instructed to take the required drug/placebo treatment for 7 days, and pharyngeal swabs and stool samples were collected on the 1st and 8th day before the trial.Swabs were collected 7 days after the end of the study.(2) a macro factor study was conducted on pharyngeal swabs to compare the abundance of microflora in the upper respiratory tract of the control group and the experimental group.Metabolomics studies were conducted on the feces of each group to search for potential biomarkers related to the action of yinhuang chemical tablets and analyze the metabolic pathways of these biomarkers in vivo.follow-upSwabs were collected from the test group once on the 7th day after the end of the experiment.
|
纳入标准:
|
(1)年龄≥18岁,≤39岁;
(2)受试者无心血管、肝脏、肾脏、呼吸、血液和淋巴、内分泌、免疫、精神、神经、胃肠道等系统慢性疾病史或严重疾病史;
(3)试验对象知情,并同意签署知情同意书。
|
Inclusion criteria
|
(1) aged >= 18, <= 39 years;
(2) the subject has no history of chronic or serious diseases of cardiovascular, liver, kidney, respiratory, blood and lymph, endocrine, immune, mental, nervous and gastrointestinal systems;
(3) the subject is informed and agrees to sign the informed consent.
|
排除标准:
|
(1)近2个月内应用抗病毒或抗生素类药物;
(2)近1个月有呼吸道感染病史;
(3)口腔及咽喉黏膜红肿或溃疡;
(4)妊娠或哺乳期、吸烟史、酗酒史、中药过敏史;
(5)精神病患者,其他不能合作或不愿合作者;
(6)近3个月内参加其他试验者。
(7)脾胃虚寒者。
|
Exclusion criteria:
|
(1) antiviral or antibiotic drugs should be used within the past two months;
(2) a history of respiratory tract infection in the past 1 month;
(3) redness or ulceration of oral and pharyngeal mucosa;
(4) pregnancy or lactation, smoking history, history of alcohol abuse, history of allergy to traditional Chinese medicine;
(5) mentally ill patients, others unable or unwilling to cooperate;
(6) other participants in the past 3 months.(7)Spleen and stomach cold deficiency.
|
研究实施时间:
Study execute time:
|
从From
2020-03-01
至To
2021-07-09
|
征募观察对象时间:
Recruiting time:
|
从From
2020-03-01
至To
2020-04-30
|